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The chloride channel 2 (CLCN2) gene codes for a protein organized in N- and C-terminal regions with regulatory functions and a
transmembrane region which forms the ring of the pore. Mutations in the gene have previously been described in patients with idiopathic familial
epilepsy. In this study we looked for new isoforms of CLCN2 and we estimated expression levels by real time PCR in brain tissue containing
epileptic foci. Samples used in this study were first analyzed and selected to exclude mutations in the coding region of the gene. Four isoforms
(skipping exons 3, 16, 22 and 6/7) were identified and quantified by Real Time PCR and compared with total expression of the gene. Expression
of the region common to all CLCN2 isoforms was 50% less in epilepsy-associated brain tissue than in controls. The ratio of the various isoforms
was slightly greater in epileptic than control tissue. The greatest difference was recorded in the temporal lobe for the isoform with skipped exon
22. Analysis of these isoforms in brain tissue containing epileptic foci suggests that CLCN2 could be implicated in epilepsy, even in the absence of
mutations.
© 2006 Elsevier B.V. All rights reserved.Keywords: Epilepsy; Chloride Channel 2; Alternative splicing; Real Time PCRSeizures are characterized by a variety of neurological
symptoms due to anomalous prolonged synchronous electrical
discharge of neurons in the cerebral cortex or brainstem.
Epilepsy, namely recurring unprovoked seizures, is a common
neurological condition. It is customary to separate symptomatic
epilepsy, due to structural or metabolic brain abnormalities,
from idiopathic epilepsy, that appears in the absence of any
detectable lesion and is thought to be primarily genetic [1–3].
Most idiopathic epilepsy appears to have complex inheritance,
about 5% of cases are monogenic. Most, but not all, gene
mutations causing inherited forms of epilepsy involve ion
channel genes [4,5].
Irrespective of cause, all predisposing factors for epilepsy act
by increasing electrical excitability of neurons or by lowering
the natural threshold of their spontaneous discharge [6]. Plasma⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.10.015membrane GABA-A receptor channels play a fundamental role
in modulating neuronal excitability, since once they are open
they tend to hyperpolarize the membrane, making it more
refractory to excitatory stimuli and therefore more resistant to
epileptic seizures. However, if these receptors are repeatedly
stimulated, the protective effect is reduced by progressive
reduction of transmembrane chloride gradient. To prevent
intracellular accumulation of chloride, it is therefore necessary
to activate special channels such as CLCN2, which ensure
chloride efflux and maintenance of the transmembrane gradient
[7,8].
The CLCN2 gene has 24 exons separated by 23 introns. The
protein is divided into two main regions, the transmembrane
region composed of alpha helix domains and the intracytoplas-
mic region which has two regulatory CBS domains separated by
a regulatory amino acid sequence. The complete ion channel
consists in a homodimer, with each monomer forming a
complete pore. The channel is open when the plasma mem-
brane is hyperpolarized or when the pH of the extracellular
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by exons 3–15. The N-terminal regulatory domain is coded by
exons 1 and 2 and the C-terminal regulatory domains by exons
16–24. Exons 16 and 17 encode amino acids from 575 to 677
and include the CBS1 regulatory region (582–637). The CBS2
regulatory region (787–840) is encoded by exons 22–24 [9–
11]. The regulatory activity of CBS domains seems to depend
on intracellular concentrations of ATP, which specifically binds
the CBS dimer, modifying the kinetics of channel opening and
closing [12,13].
In different animals, CLCN2 gene homologues are known
to have splicing variants of different functional significance
[14–17]. For example, in rats, skipping of exon 2 of this gene
causes loss of a regulatory region that impairs channel function
and destroys the transmembrane chloride gradient.
Under physiological conditions, the exon-2-skipped iso-
form prevails over the one with all exons in the fetal
brain, when neurons are migrating to build synapses before
there is any intense electrical activity [18]. In humans,
only an exon-3-skipped isoform is known and it causes
complete loss of channel electrical activity. Only three
mutations of this gene have been discovered, all in the C-
terminal region (R688G, E718D and G715E) [19,20]. Func-
tional study of G715E showed that it reduces affinity of the
CBS2 domain for ATP, modifying channel opening kinetics
[19,21,22].Table 1
Cerebral biopsies used in this study
Abbreviation Age Sex
Frontal lobe
Control 3 65 F
C.C.2 81 F
T.D.2 59 M
Patient 2 f 62 M
Z.A. 71 F
H.A. 49 F
Temporal lobe
Control S.B. 2 63 M
C.C.3 81 F
T.D.3 59 M
Patient L.M. 67 M
A.U. 71 F
R.A. 73 M
Parietal lobe
Control S.B. 2 63 M
S.A. 53 M
C.C.4 81 F
Patient B.L. 57 F
R.R. 48 M
G.A. 62 M
Occipital lobe
Control C.C.5 81 F
T.D.5 59 M
S.B. 2 63 M
Patient B.A. 58 F
A.A 56 M
S.R. 72 MIn the present study we looked for new isoforms of CLCN2
gene and estimated expression levels by Real Time PCR in brain
tissue containing epileptic foci and brain autopsy specimens of
accident victims. Specimens of brain tissue containing epileptic
foci and the corresponding control tissue were provided by the
Institutes of Neurosurgery and Pathology, respectively. Both
institutes obtained ethical committee approval for the study and
informed consent from the patients before surgery and from
the families of the accident victims.
All specimens weighed 50–100 mg. They were immersed
in RNA-later transport medium (Ambion) in a transport
container kept at 4 °C. Transport time from the hospital to the
laboratory was always less than 3 h as suggested in other
papers [23]. For each specimen of brain tissue containing
epileptic foci, excised by neurosurgeons for therapeutic
purposes, pathologists provided a specimen from the cor-
responding area of accident victim brains. None of the victims
had neurological diseases or were taking drugs that act on the
nervous system. The autopsy samples were obtained 24–28 h
after death. Twenty-four specimens (12 from epileptics and 12
from autopsies) were analysed. The surgical material was
obtained from four lobes of the brain (frontal, temporal,
parietal and occipital) and was compared with that obtained
from the corresponding lobes of autopsy brains (Table 1).
In the laboratory, specimens were immediately homogenised
in a Potter–Elvejem blender. DNA and RNA were extractedPathology Cause of death
– Myocardial infarction
– Valvulopatia aortica
– Myocardial infarction
Lung cancer metastasis –
Glioblastomas –
Astrocytomas –
– Myocardial infarction
– Myocardial infarction
– Myocardial infarction
Gliosis –
Gliosis –
Astrocytosis –
– Myocardial infarction
– Aortic rupture
– Aortic dissection
Astrocytomas –
Glioblastomas –
Astrocytomas –
– Aortic rupture
– Myocardial infarction
– Myocardial infarction
Astrocytomas –
Occipital abscess –
Astrocytomas –
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gen). RNA concentration and ratio were determined by
spectrophotometry and 1 μg total RNA was run in agarose gel
to check its integrity. RNA samples found to be of high quality
were retrotranscribed using 1 μg total RNA in 60 μl reagent
containing random hexamers and 200 U M-MuLV reverse
transcriptase (Fermentas). Conditions were 25 °C for 25 min,
42 °C for 60 min, and 70 °C for 10 min.
Extracted DNAwas PCR analysed for mutations in CLCN2,
using a set of primers specific for all 24 exons of the gene
coupled with direct sequencing in an automatic ABI PRISM
3130. Detection of a mutation was a criterion for exclusion from
subsequent steps, but, since PCR and direct sequencing did not
reveal any mutations, all specimens were considered suitable for
the study.
To identify isoforms of CLCN2 in cDNA of human brain
tissue, we performed RT-PCR using a set of primers for
different exons. PCRs were performed in a reaction final
volume of 25 μl with GOLD Taq Polymerase (Applied
Biosystems). Primers were used at 300 nM final concentra-
tion. PCRs were performed under the following conditions:
95 °C for 10 min, 35 repeated cycles at 95 °C for 30 s, 60 °C
for 30 s and 72 °C for 30 s. To allow the detection of extra
bands of lower than expected size (possible isoforms), the
amplificates were separated by agarose gel electrophoresis.
The bands were excised from the gel with a razor blade andFig. 1. Schematic representation of CLCN2 mRNAs identified in hupurified with a GFX kit (Amersham Pharmacia Biotech). The
purified gel fragment was sequenced to determine the skipped
exon. Four alternative transcripts of the gene were found in
extracted RNA, in which exon 3 (sequenced with primers on
exons 2 and 4), exon 6/7 (sequenced with primers on exons 4
and 8), exon 16 (sequenced with primers on exons 15 and
18) and exon 22 (sequenced with primers on exons 18 and
23) were skipped. These alternative transcripts were found in
all specimens (patients and controls) representing the four
lobes of the brain. When transcripts were amplified in
correspondence with 5′ or 3′ of ORF, skipping of exons 3
and 16 was found in the same transcript but skipping of
the other two exons was not found in a single transcript
(Fig. 1).
Expression of CLCN2 in the different lobes of normal and
epileptic brains was investigated by semi-quantitative RT-PCR
(method of SYBR Green) using a pair of primers on two
exons present in all isoforms. Semi-quantitative real time
PCR was carried out in a 96-well optical reaction plate using
an ABI Prism 7700 sequence detector (Applied Biosystems).
Primers were designed using Primer Express (Applied
Biosystems). Expression of human housekeeping gene
GAPDH was used as reference. PCR primer sequences for
CLCN2-WT, CLCN2-SK3, CLCN2-SK6/7, CLCN2-SK16,
CLCN2-SK22 and GAPDH are available on request. Reac-
tions were performed in 25 μl with 1.5 μl cDNA, 2X SYBRman brain and corresponding ESTs present in NCBI database.
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California, U.S.A.) and 300 nM primers. PCR conditions
were: 2 min at 50 °C, 10 min at 95 °C and 50 cycles of 15 s
at 95 °C, 15 s at 57 °C and 50 s at 60 °C. Target and reference
genes were amplified in separate wells. All reactions were
performed in triplicate. Reaction mixture without cDNA was
used as negative control in each run. Standard curves were
plotted as follows: GAPDH y=−3.194x+23.516, r2=0.99;
CLCN2-WT y=−2.5361x+34.79, r2=0.98; CLCN2-SK3 y=
−3.3787x+30.285, r2=0.99; CLCN2-SK6/7 y=−3.28858x+
28.35, r2=0.99; CLCN2-SK16 y=−2.8075x+39.90, r2=0.99;
CLCN2-SK22 y=−2.9907x+33.68, r2=0.99. The 2-DDCt
method was used to quantify gene expression compared with
GAPDH. Statistical analysis of all data was performed by
ANOVA.
Taking expression in the occipital lobe as 1, the other lobes
gave expressions of 2.3 (frontal), 2.7 (parietal) and 4.5
(temporal). In all specimens from epileptics there was a
reduction in expression of about 50% with respect to the
corresponding lobe of controls for all gene isoforms (Fig. 2).
To determine whether expression ratios of the isoforms
varied as well as expression levels, we designed primers to
selectively amplify each transcript. Expression of each isoform
was compared with total gene expression (primers designed on
a region common to all isoforms). The results (Fig. 3) showed
only minor differences in the distribution of isoforms between
the four lobes: comparing expression of isoforms with exon
skipping and the isoform including all exons (consensus
sequence), the most frequent was that in which exon 3 was
skipped (about 18%) followed by exon 16 (about 15%), exon 22
(12% except in the temporal lobe where it was 15%) and exon 6/
7 (about 2%). Specimens from epileptics showed expression
ratios of the various isoforms similar to those of controls, except
for a slight increase in isoforms with exon skipping. The
isoform in which exon 22 was skipped reached 20% in the
temporal lobe (Fig. 3).
Loss-of-function mutations in the CLCN2 gene cause
epilepsy [19]. We reasoned that lower expression and alteredFig. 2. CLCN2 gene expression in biopsies from four cerebral areas of patients
with epilepsy and of control individuals deceased for accidental causes.splicing of this transcript may also occur as an epileptogenic
mechanism in conditions as diverse as tumors, inflammation, or
ischemia, even in the absence of gene mutations. We therefore
studied specific CLCN2 mRNAs extracted from epileptic
human brains, both qualitatively and quantitatively. We com-
pared these results with those obtained from autopsy brain
tissue of healthy subjects.
Qualitative study of the gene enabled us to identify four
different transcripts in the four brain lobes considered. One
contained all 24 exons, in another exons 3 and 16 were missing
and in the last two exons 6/7 and 22 were missing. The effective
existence in vivo of the alternative transcripts identified is
supported by the identification of corresponding human ESTs
(Fig. 1). We did not determine whether these transcripts are
actually used to generate ion channels with different activities,
but the existence of functionally different isoforms of the
homologous channel has been demonstrated in various lower
organisms [14,18].
Quantitative study of expression of the common isoform of
CLCN2 by Real Time PCR and the ratio of minor isoforms to
the common one in four lobes of normal and epileptic human
brains provided information on the pathophysiological role of
CLCN2 and in support of our hypothesis. The gene was most
expressed in the temporal, followed by the parietal, frontal and
occipital lobes. This is in line with published data on rat brain
used as an experimental model of human epilepsy and shows
that the gene is expressed more in lobes that often generate
seizures (temporal lobe) where it presumably plays the role of
seizure inhibitor [24]. In biopsies obtained near epileptic foci
we noticed a strong reduction in gene expression in all lobes
examined. Since we did not study protein expression, we cannot
attribute greater susceptibility to seizures to reduced gene
expression, though this is perfectly in line with what was found
in the rat experimental model [25].
Three isoforms (CLCN2-SK6/7, CLCN2-SK16 and
CLCN2-SK22) are described here for the first time. Study of
the various ratios of the isoforms with respect to expression of
the common isoform did not show substantial differences
between epileptic and control brain tissue, though there was a
slight general increase in the ratio of isoforms with exon
skipping in the epilepsy specimens, especially in the case of
exon 22 skipping in the temporal lobe. This is particularly
interesting because exon 22 codes for the CBS2 regulatory
domain that plays a major role in regulating the opening kinetics
of the chloride channel in response to intracytoplasmic
availability of ATP.
Though we did not do electrophysiological studies on the
protein coded by this isoform, the protein with mutation G715E
which is also involved in the CBS2 domain has been studied
and radical alteration of channel opening kinetics has been
demonstrated [19,21,22]. By similarity, we postulate that the
isoform we identified may indeed have major functional
significance.
In conclusion, this preliminary study provides support for
the hypothesis that the CLCN2 gene could be implicated in
epilepsy, even in the absence of mutations (which are very
rare), but due to alteration of its expression or of the ratio of
Fig. 3. Expression of isoforms of CLCN2 gene in biopsies from controls (blue) and from patients (red) for the four cerebral areas. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
19M. Bertelli et al. / Biochimica et Biophysica Acta 1772 (2007) 15–20its isoforms. We should also say that, due to the fact that we
used almost exclusively brain specimens from resected
tumors, we cannot rule out the possibility that the observed
decrease in mRNA levels may be due to the lesion itself more
than to the epilepsy. To exclude this possibility and to
confirm our hypothesis, it will be necessary to study a greater
number of specimens and to complete the present study with
protein studies and electrophysiological experiments on theplasma membrane, with selective expression of cloned
isoforms.
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